These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
509 related articles for article (PubMed ID: 16848809)
1. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. ter Borg PC; Schalm SW; Hansen BE; van Buuren HR; Am J Gastroenterol; 2006 Sep; 101(9):2044-50. PubMed ID: 16848809 [TBL] [Abstract][Full Text] [Related]
2. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR; Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346 [TBL] [Abstract][Full Text] [Related]
3. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Poupon RE; Bonnand AM; Chrétien Y; Poupon R Hepatology; 1999 Jun; 29(6):1668-71. PubMed ID: 10347106 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847 [TBL] [Abstract][Full Text] [Related]
5. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499 [TBL] [Abstract][Full Text] [Related]
6. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401 [TBL] [Abstract][Full Text] [Related]
7. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Kilmurry MR; Heathcote EJ; Cauch-Dudek K; O'Rourke K; Bailey RJ; Blendis LM; Ghent CN; Minuk GY; Pappas SC; Scully LJ; Steinbrecher UP; Sutherland LR; Williams CN; Worobetz LJ Hepatology; 1996 May; 23(5):1148-53. PubMed ID: 8621147 [TBL] [Abstract][Full Text] [Related]
8. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. Batts KP; Jorgensen RA; Dickson ER; Lindor KD Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409 [TBL] [Abstract][Full Text] [Related]
9. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. Corpechot C; Chazouillères O; Poupon R J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194 [TBL] [Abstract][Full Text] [Related]
10. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Parés A; Caballería L; Rodés J Gastroenterology; 2006 Mar; 130(3):715-20. PubMed ID: 16530513 [TBL] [Abstract][Full Text] [Related]
11. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis. Jorgensen R; Angulo P; Dickson ER; Lindor KD Am J Gastroenterol; 2002 Oct; 97(10):2647-50. PubMed ID: 12385454 [TBL] [Abstract][Full Text] [Related]
12. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Huet PM; Vincent C; Deslaurier J; Coté J; Matsutami S; Boileau R; Huet-van Kerckvoorde J Gastroenterology; 2008 Nov; 135(5):1552-60. PubMed ID: 18722374 [TBL] [Abstract][Full Text] [Related]
13. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557 [TBL] [Abstract][Full Text] [Related]
15. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324 [TBL] [Abstract][Full Text] [Related]
16. Survival probabilities of Pugh-Child-PBC classified patients in the euricterus primary biliary cirrhosis population, based on the Mayo clinic prognostic model. Euricterus Project Management Group. Reisman Y; van Dam GM; Gips CH; Lavelle SM; Euricterus PM Hepatogastroenterology; 1997; 44(16):982-9. PubMed ID: 9261586 [TBL] [Abstract][Full Text] [Related]
17. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Chan CW; Gunsar F; Feudjo M; Rigamonti C; Vlachogiannakos J; Carpenter JR; Burroughs AK Aliment Pharmacol Ther; 2005 Feb; 21(3):217-26. PubMed ID: 15691295 [TBL] [Abstract][Full Text] [Related]
18. The natural history of PBC: has it changed? Lee YM; Kaplan MM Semin Liver Dis; 2005 Aug; 25(3):321-6. PubMed ID: 16143947 [TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. Papatheodoridis GV; Hadziyannis ES; Deutsch M; Hadziyannis SJ Am J Gastroenterol; 2002 Aug; 97(8):2063-70. PubMed ID: 12190178 [TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Kaplan MM; Cheng S; Price LL; Bonis PA Hepatology; 2004 Apr; 39(4):915-23. PubMed ID: 15057894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]